Publication date: Sep 23, 2025
The effects of telemedicine on health expenditures and health outcomes are an important policy question. Many countries loosened regulations on the use of telemedicine during the COVID-19 pandemic, thereby offering an opportunity to evaluate these effects via a natural experiment. This study aimed to assess the effect of greater telemedicine use on area-level health expenditures and health outcomes related to common chronic conditions in Japan during the COVID-19 pandemic. We compared prefectures (area levels of government) with higher prepandemic telemedicine rates (fiscal year [FY] 2019) versus those with lower rates and conducted a difference-in-differences analysis of the change in prefecture-level health expenditures from FY2017 to FY2022 and health outcomes from FY2017 to FY2021. The participants were the total population in Japan from FY2017 to FY2022 (n=126 million), and the exposure was the increase in telemedicine use following the government’s relaxation of restrictions on telemedicine use as an exceptional measure during the COVID-19 pandemic. Our main outcomes were the share of outpatient claims that were for telehealth services; total, inpatient, and outpatient annual prefecture-level health expenditures; all-cause mortality, glycated hemoglobin, systolic blood pressure, and low-density lipoprotein cholesterol. Treatment prefectures (n=15, population of 62 million) were defined as those with greater-than-median telemedicine use before the pandemic, while control prefectures (n=32, population of 64 million) were defined as those with less-than-median telemedicine use. Treatment and control prefectures shared similar demographic characteristics before the pandemic. The growth in telemedicine after 2020 as a share of outpatient claims increased among the treatment prefectures by 0. 35 percentage points more than among control prefectures, which represented more than a threefold increase in telemedicine use compared to the prepandemic median. In difference-in-differences analyses, this difference was associated with a 1. 0% relative decrease (95% CI 0. 3%-1. 8%) in total health expenditure (P=. 006) and a 1. 1% relative decrease (95% CI 0. 2%-2. 0%) in inpatient expenditure (P=. 02). Outpatient expenditures showed no significant difference as a result of increased telemedicine adoption. Most health outcomes-all-cause mortality, glycated hemoglobin, systolic blood pressure, diastolic blood pressure, and low-density lipoprotein cholesterol-did not show any significant changes. Areas in Japan with greater expansion of telemedicine use during the pandemic experienced a significant decrease in both inpatient and total health care spending compared with areas with less telemedicine use, without harming health outcomes.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 Pandemic |
| disease | MESH | chronic conditions |
| disease | IDO | blood |
| drug | DRUGBANK | Methylphenidate |
| disease | MESH | anxiety disorders |
| disease | MESH | depression |
| disease | MESH | ischemic stroke |
| disease | MESH | medication errors |
| disease | IDO | country |
| disease | MESH | emergencies |
| disease | MESH | lifestyle |
| disease | IDO | intervention |